Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William A Zammarrelli

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|February 15, 2023
Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial CancerSushmita Gordhandas, William A Zammarrelli, Eric V Rios-Doria, et al.
Gynecologic Oncology|May 16, 2021
Sentinel lymph node biopsy in patients with endometrial cancer and an indocyanine green or iodinated contrast reaction - A proposed management algorithmWilliam A Zammarrelli, Anoushka M Afonso, Vance Broach, et al.
Gynecologic Oncology|December 24, 2022
Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary studySarah Ehmann, Kelly Shay, Qin Zhou, et al.
Gynecologic Oncology|September 25, 2023
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancerWilliam A Zammarrelli, Weining Ma, Kevin Espino, et al.
Gynecologic Oncology|March 2, 2022
Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcomaWilliam A Zammarrelli, Michelle Greenman, Eric Rios-Doria, et al.
Medrxiv : the Preprint Server for Health Sciences|June 17, 2024
Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancerNicolás Gómez-Banoy, Eduardo Ortiz, Caroline S Jiang, et al.
The Journal of Clinical Investigation|June 20, 2024
Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancerNicolás Gómez-Banoy, Eduardo J Ortiz, Caroline S Jiang, et al.
JCO Precision Oncology|October 14, 2022
Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular ClassificationWilliam A Zammarrelli, Sarah H Kim, Arnaud Da Cruz Paula, et al.
Gynecologic Oncology|March 13, 2025
The genomic landscape of distant metastatic endometrial cancerWilliam A Zammarrelli, Subhiksha Nandakumar, Elizabeth Kertowidjojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial CancerAngela K Green, Qin Zhou, Alexia Iasonos, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of the National Comprehensive Cancer Network : JNCCN|February 15, 2023
Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial CancerSushmita Gordhandas, William A Zammarrelli, Eric V Rios-Doria, et al.
Gynecologic Oncology|May 16, 2021
Sentinel lymph node biopsy in patients with endometrial cancer and an indocyanine green or iodinated contrast reaction - A proposed management algorithmWilliam A Zammarrelli, Anoushka M Afonso, Vance Broach, et al.
Gynecologic Oncology|December 24, 2022
Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary studySarah Ehmann, Kelly Shay, Qin Zhou, et al.
Gynecologic Oncology|September 25, 2023
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancerWilliam A Zammarrelli, Weining Ma, Kevin Espino, et al.
Gynecologic Oncology|March 2, 2022
Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcomaWilliam A Zammarrelli, Michelle Greenman, Eric Rios-Doria, et al.
Medrxiv : the Preprint Server for Health Sciences|June 17, 2024
Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancerNicolás Gómez-Banoy, Eduardo Ortiz, Caroline S Jiang, et al.
The Journal of Clinical Investigation|June 20, 2024
Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancerNicolás Gómez-Banoy, Eduardo J Ortiz, Caroline S Jiang, et al.
JCO Precision Oncology|October 14, 2022
Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular ClassificationWilliam A Zammarrelli, Sarah H Kim, Arnaud Da Cruz Paula, et al.
Gynecologic Oncology|March 13, 2025
The genomic landscape of distant metastatic endometrial cancerWilliam A Zammarrelli, Subhiksha Nandakumar, Elizabeth Kertowidjojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial CancerAngela K Green, Qin Zhou, Alexia Iasonos, et al.
Pageof 2